News Snapshot:
JS016, a treatment for Covid-19 has been approved for emergency use by 15 countries, with the combination of another neutralizing antibody, according to information relayed by the CCTV News channel on November 19. Protected by the Chinese Independent Intellectual Property Rights Law, this treatment was co-developed by Junshi Biosciences and the Institute of Microbiology of the Chinese Academy of Sciences. JS016 is a recombinant, monoclonal neutralizing antibody against Covid-19. This treatment belongs to the class of medicines called monoclonal antibodies which are widely used to treat cancer, rheumatoid arthritis and many other conditions. According to researcher Daniel Skovronsky, this type...
